Literature DB >> 18597045

Intracoronary bivalirudin for no reflow reversal: a second chance to treat this disorder?

Bernardo Cortese1, Andrea Picchi, Andrea Micheli, Ugo Limbruno.   

Abstract

No reflow, defined as failure to restore normal myocardial blood flow despite removal of coronary obstruction, is a not rare complication of ST-elevation acute myocardial infarction. We here describe the case of an old patient experiencing inferior and right ventricle myocardial infarction complicated by cardiogenic shock, anaemia and thrombocytopenia. We managed it with urgent PCI using thrombus aspirator, that determined onset of no reflow, that we successfully managed with intracoronary bivalirudin. We showed how bivalirudin, a drug whose use is increasing in the catheterization laboratories, could be safely used via the intracoronary route to treat no reflow phenomenon due to distal microembolization in a complex patient.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18597045     DOI: 10.1007/s11239-008-0243-9

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  4 in total

1.  The role of vasodilators in the prevention and treatment of no-reflow following percutaneous coronary intervention.

Authors:  S A Harding
Journal:  Heart       Date:  2006-04-10       Impact factor: 5.994

Review 2.  The no-reflow phenomenon: A basic mechanism of myocardial ischemia and reperfusion.

Authors:  Thorsten Reffelmann; Robert A Kloner
Journal:  Basic Res Cardiol       Date:  2006-09       Impact factor: 17.165

Review 3.  Direct thrombin inhibition during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.

Authors:  Bruce E Lewis; Marcie J Hursting
Journal:  Expert Rev Cardiovasc Ther       Date:  2007-01

4.  Intracoronary boluses of adenosine and sodium nitroprusside in combination reverses slow/no-reflow during angioplasty: a clinical scenario of ischemic preconditioning.

Authors:  Keyur H Parikh; Milan C Chag; Kanan J Shah; Urmil G Shah; Hemang A Baxi; Anish H Chandarana; Ajay M Naik; Joyal N Shah; Hetal D Shah; Ramesh K Goyal
Journal:  Can J Physiol Pharmacol       Date:  2007 Mar-Apr       Impact factor: 2.273

  4 in total
  2 in total

1.  Elevating local concentrations of GPIIb-IIIa antagonists counteracts platelet thrombus stability.

Authors:  Henry E Speich; Ronit R Furman; Lindsey T Lands; Geoffrey D Moodie; Lisa K Jennings
Journal:  J Thromb Thrombolysis       Date:  2013-07       Impact factor: 2.300

2.  The REFLO-STEMI trial comparing intracoronary adenosine, sodium nitroprusside and standard therapy for the attenuation of infarct size and microvascular obstruction during primary percutaneous coronary intervention: study protocol for a randomised controlled trial.

Authors:  Sheraz A Nazir; Jamal N Khan; Islam Z Mahmoud; John P Greenwood; Daniel J Blackman; Vijay Kunadian; Martin Been; Keith R Abrams; Robert Wilcox; A A Jennifer Adgey; Gerry P McCann; Anthony H Gershlick
Journal:  Trials       Date:  2014-09-25       Impact factor: 2.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.